Tuesday, June 23, 2026

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

Top South Korea Regulator’s $28.9M Fortune: $20M in Cash, Plus Tesla and Apple on the Side

Lee Chan Jin, FSS Chairman, holds 38.5 billion KRW in assets, focusing on bank stocks and semiconductors, with U.S. stocks for diversification.

Why Ebola Now? SK Bioscience Joins a $30 Million Global Push to Rethink Ebola Vaccine Production

SK Bioscience secures funding to enhance Ebola vaccine production, improving yield and stability for better accessibility amid outbreaks.

Tag: societal shifts

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.